Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kaye

Showing results (741-750 of 853) with videos related to

Pageof 86
Sort By:
British Journal of Cancer|November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trialsE Geuna, D Roda, S Rafii, et al.
Current Eye Research|January 6, 2022
Delivering Endothelial Keratoplasty Grafts: Modern Day Transplant DevicesMohit Parekh, Vito Romano, Kareem Hassanin, et al.
British Journal of Cancer|August 1, 1994
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group StudyC N Sternberg, W W ten Bokkel Huinink, J F Smyth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2012
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancerS B Kaye, C J Poole, A Dańska-Bidzińska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer studyS B Kaye, G M Mead, S Fossa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2012
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysisBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Cancer Research|May 15, 1987
Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III StudyG Stoter, R Sylvester, D T Sleijfer, et al.
Science (New York, N.Y.)|October 14, 2017
Innovative scattering analysis shows that hydrophobic disordered proteins are expanded in waterJoshua A Riback, Micayla A Bowman, Adam M Zmyslowski, et al.
Progress in Clinical and Biological Research|January 1, 1988
A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancerG Stoter, R Sylvester, D T Sleijfer, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Pageof 86

Showing results (741-750 of 853) with videos related to

Sort By:
Pageof 86
British Journal of Cancer|November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trialsE Geuna, D Roda, S Rafii, et al.
Current Eye Research|January 6, 2022
Delivering Endothelial Keratoplasty Grafts: Modern Day Transplant DevicesMohit Parekh, Vito Romano, Kareem Hassanin, et al.
British Journal of Cancer|August 1, 1994
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group StudyC N Sternberg, W W ten Bokkel Huinink, J F Smyth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2012
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancerS B Kaye, C J Poole, A Dańska-Bidzińska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer studyS B Kaye, G M Mead, S Fossa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2012
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysisBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Cancer Research|May 15, 1987
Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III StudyG Stoter, R Sylvester, D T Sleijfer, et al.
Science (New York, N.Y.)|October 14, 2017
Innovative scattering analysis shows that hydrophobic disordered proteins are expanded in waterJoshua A Riback, Micayla A Bowman, Adam M Zmyslowski, et al.
Progress in Clinical and Biological Research|January 1, 1988
A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancerG Stoter, R Sylvester, D T Sleijfer, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Pageof 86